as of —
₹—
Change
—
Day Open
₹—
Day High
₹—
Day Low
₹—
NSE Close — 25 Sep 2026
₹1,281.0
Change
-14.3 (-1.1%)
Open
₹1,295.3
Prev. Close
₹1,295.3
Day High
₹1,304.1
Day Low
₹1,274.5
Volume Analysis
Traded
34,476
Delivered
18,887
Delivery %
54.78%
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Strengths, Weaknesses, Opportunities & Threats
Strengths (0)
No signal for this stock
Weaknesses (0)
No signal for this stock
Opportunities (2)
- •Strong 3-year EPS growth (20.3%)
- •Strong 3-year revenue growth (20.7%)
Threats (1)
- •FII holding has been falling
Rule-based signals from the fundamentals below — not investment advice.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹1,328.16 | ₹1,316.13 | ₹1,298.56 | ₹1,286.53 | ₹1,268.96 | ₹1,256.93 | ₹1,239.36 |
| Fibonacci | ₹1,316.13 | ₹1,304.82 | ₹1,297.84 | ₹1,286.53 | ₹1,275.22 | ₹1,268.24 | ₹1,256.93 |
| Camarilla | ₹1,289.14 | ₹1,286.43 | ₹1,283.71 | ₹1,286.53 | ₹1,278.29 | ₹1,275.57 | ₹1,272.86 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
+73.47%
1 Week
+6.9%
1 Month
+21.41%
3 Months
+30.92%
6 Months
+81.97%
1 Year
+51.59%
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Stock Vitals
Computed from the latest available annual financials.
Graham Number
₹325.34
Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.
DuPont ROE Breakdown
13.17%
Net margin 8.81% × asset turnover 0.89x × equity multiplier 1.68x
Company Overview
Sector
Healthcare
Market Cap
₹7,402 Cr
P/E (TTM)
48.1
ROE
13.7%
Book Value
₹191.0
Face Value
₹10.0
Source: Screener.in (Consolidated figures) — data as of 24 Sep 2026. Not investment advice.
TopFund Analysis
Innova Captab Limited lands in the middle of the pack on TopFund's composite fundamentals check within the Healthcare sector, at 63/100. The strongest factor is Financial Strength (99/100), while Valuation (8/100) is the weakest area to weigh before deciding. FII holding has been falling.
TopFund Score — Fundamentals Quality
63/100 — AverageData confidence: 79/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.
As of 27 Sep 2026 · How we calculate this →
Financial Strength
Growth
Valuation
Cash Flow
Corporate Governance
Momentum
Institutional Ownership
Business Quality
Risk & Volatility
Liquidity
From Screener.in
- +Company is expected to give good quarter
- +Company has delivered good profit growth of 32.5% CAGR over last 5 years
- −Company might be capitalizing the interest cost
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
Innova Captab will attend Anand Rathi G-200 Summit 2026 on 21 September 2026 in Mumbai.
Pursuant to the regulation 30 read with schedule III, Part A, Para A and regulation 47 of SEBI (LODR) Regulations, 2015 ("Listing regulations") ....
Innova Captab schedules 22nd AGM on 30 September 2026; annual report 2025-26 and e-voting dates shared.
Innova Captab submitted its BRSR for FY 2025-26, forming part of the Integrated Annual Report.
Source: BSE regulatory filings, via Screener.in.
Quarterly Results
Last several quarters
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 233 | 283 | 302 | 263 | 294 | 318 | 316 | 315 | 352 | 380 | 450 | 448 | 471 |
| Expenses + | 202 | 242 | 258 | 225 | 252 | 268 | 270 | 267 | 299 | 329 | 381 | 383 | 398 |
| Operating Profit | 31 | 40 | 45 | 38 | 42 | 50 | 47 | 48 | 52 | 52 | 69 | 65 | 73 |
| OPM % | 13.0% | 14.0% | 15.0% | 14.0% | 14.0% | 16.0% | 15.0% | 15.0% | 15.0% | 14.0% | 15.0% | 15.0% | 16.0% |
| Other Income + | 1 | 3 | 2 | 6 | 2 | 2 | 4 | 3 | 4 | 4 | 2 | 2 | 2 |
| Interest | 5 | 9 | 7 | 1 | 0 | 0 | 0 | 2 | 3 | 6 | 4 | 5 | 4 |
| Depreciation | 3 | 5 | 5 | 3 | 5 | 5 | 5 | 10 | 11 | 11 | 11 | 11 | 12 |
| Profit before tax | 25 | 30 | 35 | 40 | 39 | 47 | 46 | 39 | 43 | 39 | 56 | 51 | 59 |
| Tax % | 28.0% | 24.0% | 29.0% | 27.0% | 25.0% | 25.0% | 25.0% | 25.0% | 27.0% | 24.0% | 24.0% | 25.0% | 25.0% |
| Net Profit + | 18 | 23 | 25 | 29 | 29 | 35 | 34 | 30 | 31 | 30 | 42 | 38 | 44 |
| EPS in Rs | 4 | 5 | 4 | 5 | 5 | 6 | 6 | 5 | 5 | 5 | 7 | 7 | 8 |
| Raw PDF | — | — | — | — | — | — | — | — | — | — | — | — | — |
Source: Screener.in — figures in ₹ Crores unless marked %.
Profit & Loss (Yearly)
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|
| Sales + | 356 | 373 | 411 | 801 | 926 | 1,081 | 1,244 | 1,630 | 1,749 |
| Expenses + | 315 | 322 | 356 | 704 | 813 | 927 | 1,057 | 1,387 | 1,490 |
| Operating Profit | 41 | 51 | 54 | 96 | 114 | 154 | 186 | 243 | 259 |
| OPM % | 11.0% | 14.0% | 13.0% | 12.0% | 12.0% | 14.0% | 15.0% | 15.0% | 15.0% |
| Other Income + | 0 | 1 | 1 | 3 | 9 | 12 | 12 | 7 | 9 |
| Interest | 6 | 5 | 4 | 6 | 20 | 21 | 2 | 17 | 18 |
| Depreciation | 11 | 10 | 6 | 8 | 11 | 16 | 25 | 45 | 46 |
| Profit before tax | 25 | 38 | 46 | 86 | 92 | 130 | 171 | 188 | 205 |
| Tax % | 20.0% | 26.0% | 26.0% | 25.0% | 26.0% | 27.0% | 25.0% | 25.0% | — |
| Net Profit + | 20 | 28 | 34 | 64 | 68 | 94 | 128 | 141 | 154 |
| EPS in Rs | 166 | 232 | 288 | 533 | 14 | 16 | 22 | 25 | 27 |
| Dividend Payout % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 8.0% | — |
Source: Screener.in — figures in ₹ Crores unless marked %.
Balance Sheet
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Reserves | 70 | 98 | 133 | 197 | 229 | 774 | 902 | 1,034 |
| Borrowings + | 72 | 54 | 46 | 199 | 237 | 245 | 338 | 344 |
| Other Liabilities + | 68 | 81 | 179 | 167 | 191 | 240 | 271 | 401 |
| Total Liabilities | 223 | 245 | 370 | 575 | 704 | 1,316 | 1,568 | 1,836 |
| Fixed Assets + | 78 | 73 | 79 | 183 | 183 | 358 | 830 | 842 |
| CWIP | 0 | 0 | 7 | 0 | 22 | 341 | 23 | 16 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 41 |
| Other Assets + | 144 | 172 | 283 | 392 | 500 | 617 | 716 | 938 |
| Total Assets | 223 | 245 | 370 | 575 | 704 | 1,316 | 1,568 | 1,836 |
| Equity Capital | 12 | 12 | 12 | 12 | 48 | 57 | 57 | 57 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Cash Flow
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 19 | 31 | 42 | 59 | 67 | 146 | 64 | 117 |
| Cash from Investing Activity + | -9 | -6 | -20 | -188 | -91 | -499 | -152 | -107 |
| Cash from Financing Activity + | -9 | -23 | -19 | 125 | 27 | 361 | 92 | -22 |
| Net Cash Flow | 1 | 1 | 3 | -5 | 3 | 8 | 4 | -12 |
| CFO/OP | 68 | 79 | 101 | 83 | 76 | 113 | 47 | 59 |
| Free Cash Flow | 11 | 27 | 23 | -21 | -11 | -141 | -108 | 55 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Public | 35.22% | 26.39% | 26.67% | 27.48% | 28.41% | 29.0% | 29.2% | 28.86% | 28.76% | 28.74% | 28.84% |
| Promoters | 50.9% | 50.9% | 50.9% | 50.9% | 50.9% | 50.9% | 50.9% | 50.9% | 50.9% | 50.9% | 50.9% |
| FII | 3.57% | 1.94% | 1.19% | 1.01% | 0.74% | 0.35% | 0.23% | 0.08% | 0.1% | 0.23% | 0.34% |
| DII | 10.31% | 20.78% | 21.24% | 20.61% | 19.96% | 19.77% | 19.67% | 20.17% | 20.24% | 20.14% | 19.92% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Healthcare — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Innova Captab Limited (this stock) | 7,402 | 48.1 | 6.78 | 13.7% |
| Bliss Gvs Pharma Ltd | 7,486 | 54.4 | 6.23 | 11.8% |
| Sanofi India Limited | 7,232 | 16.4 | 8.4 | 47.1% |
| Nephrocare Health Serv L | 7,005 | 82.3 | 6.28 | 8.83% |
| Sun Pharma Adv.res.co.ltd | 6,784 | 4.25 | 5.06 | 279.0% |
| Kovai Medical Center & Ho | 6,653 | 115.0 | 23.07 | 22.2% |
| Morepen Lab. Ltd | 6,596 | 56.2 | 5.26 | 5.33% |
Which Mutual Funds Hold Innova Captab Limited?
Frequently Asked Questions about Innova Captab Limited
Innova Captab Limited (INNOVACAP) closed at ₹1,281.0 on NSE on 25 September 2026, down 14.3 (1.1%) from the previous close.
Innova Captab Limited trades on the NSE (National Stock Exchange of India) under the symbol INNOVACAP.
Innova Captab Limited has a trailing twelve-month P/E (price-to-earnings) ratio of 48.1.
Innova Captab Limited has a dividend yield of 0.15%.
Innova Captab Limited's 52-week high is ₹1,354.0 and its 52-week low is ₹608.0.
Innova Captab Limited has a market capitalisation of ₹7,402 crore.
Innova Captab Limited has a TopFund Quality Score of 63/100 (Average), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Innova Captab Limited?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.